NewAmsterdam Pharma (NASDAQ:NAMS), Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel peptide-based therapies for metabolic and endocrine disorders. Headquartered in Palo Alto, California, the company employs a multidisciplinary approach to engineer long-acting peptides designed to restore hormonal balance and optimize metabolic control. Its lead clinical candidates target conditions such as postprandial hyperinsulinemia, post-bariatric hypoglycemia, and other glycemic regulation disorders for which limited treatment options currently exist.
Founded in 2016 by a team of endocrinologists and peptide chemists, NewAmsterdam Pharma has assembled a pipeline of proprietary molecules that leverage advanced formulation technologies to extend half-life and improve patient convenience. The company’s leading investigational agent is a once-weekly injectable peptide analog that has demonstrated promising Phase 1 and 2 results in reducing excessive insulin secretion and stabilizing post-meal glucose excursions. Additional preclinical programs focus on FGF21-based analogs for nonalcoholic steatohepatitis (NASH) and other obesity-related comorbidities.
NewAmsterdam serves a global patient population through clinical trial sites across North America, Europe, and Asia, and maintains strategic partnerships with academic medical centers and contract research organizations. These collaborations provide access to advanced imaging, biomarker development, and real-world evidence support, accelerating the translation of novel peptide candidates from bench to bedside. The company holds worldwide development and commercialization rights for its internal pipeline.
Leadership at NewAmsterdam Pharma includes George Bischof, M.D., co-founder and Chief Executive Officer, who brings over two decades of experience in translational endocrinology, and Laura Tuttle, Chief Financial Officer, whose background spans corporate finance and biotech strategy. The management team is complemented by a scientific advisory board of renowned experts in peptide therapeutics, metabolism, and clinical pharmacology, guiding the company’s efforts to address significant unmet needs in metabolic disease treatment.
